Cargando...
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children
Rituximab, a chimeric anti-CD20 monoclonal antibody originally licensed for lymphoma, is emerging as a novel steroid-sparing agent for idiopathic nephrotic syndrome in children. The potential use of anti-CD20 monoclonal antibodies in idiopathic nephrotic syndrome has contributed to shifting the view...
Gardado en:
| Publicado en: | Clin J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Nephrology
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822672/ https://ncbi.nlm.nih.gov/pubmed/26585985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08500815 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|